KOR

e-Article

POSB320 Matching-Adjusted Indirect Comparison of Guselkumab Versus Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Change in Baseline PASI from Week 4-40
Document Type
Abstract
Source
In Value in Health January 2022 25(1) Supplement:S206-S206
Subject
Language
ISSN
1098-3015